Crisaborole

Category: topical

Aliases: Eucrisa

Pharmacological Mechanism

Topical PDE4 inhibitor — raises keratinocyte cAMP → reduced inflammatory cytokine release. Approved for atopic dermatitis as steroid-sparing alternative. Application-site burning (~5%) is the most common adverse effect.

Half-Life (t½)

TD: 14h

Dosing Guidelines

• TD: Typical 40mg (Range: 20 - 60 mg)

Target Organ Systems

• integumentary
• immune-hematologic